Special Issue:guidebook/guide Interpretation
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2023 Report) (GOLD 2023) maintains the basic framework of GOLD 2022, but with major revisions in the definition, assessment, initial therapy and follow-up management of chronic obstructive lung disease (COPD) as follow: (1) Chapter 1: The definition and overview section was rewritten to propose a new definition of COPD, incorporating new background information, therapeutic strategies and classifications for COPD, with the addition of content on chronic bronchitis; (2) Chapter 2: Content on screening and case-finding of COPD has been included, the ABCD assessment tool has been revised to the ABE assessment tool (no further grouping of high-risk population of acute exacerbation of COPD based on symptom levels), information on imaging and computed tomography scans (CT) has been included in the diagnosis and assessment section; (3) Chapter 3: Recommendations for Streptococcus pneumoniae vaccination have been updated, information on therapeutic interventions to reduce COPD mortality has been included, issues related to inhalation delivery have been updated, content on inhaled medications adherence and remote rehabilitation has been included, information on interventional and surgical therapies of COPD has been expanded in the prevention and maintenance treatment section; (4) Chapter 4: Information on the selection of inhalation devices has been included, information on initial drug therapy and follow-up drug therapy has been updated in the management of stable COPD section; (5) Chapter 5: A new definition of and set of acute exacerbation of COPD assessment parameters have been proposed, information on differential diagnoses of acute exacerbation of COPD has been expanded in the acute exacerbation of COPD section management; (6) Chapter 6 and 7: Updating content on COPD and complications (Chapter 6), COPD (Chapter 7) and COVID-19 based on the latest evidence. The above updates will be an important guide to the clinical management of COPD.
Low-density lipoprotein cholesterol (LDL-C) is a pathogenic risk factor for atherosclerotic cardiovascular disease (ASCVD). In recent decades, the prevalence of dyslipidemia in the Chinese population increases continuously, it is urgent to improve blood lipid management in China. It is particularly important to carry out standardized blood lipid management at primary healthcare institutions. The Chinese Guideline for Lipid Management (Primary Care Version 2024) concisely recommends that LDL-C should be the preferred intervention target in lipid management, and the target values of LDL-C should be determined based on ASCVD risk stratification. The present guideline recommends to use moderate-intensity statins at the beginning of treatment on the basis of lifestyle intervention. If the LDL-C target level can not be reached, other lipid-lowering drugs like cholesterol absorption inhibitors or (and) proprotein convertase subtilisin/kexin type 9 inhibitors should be jointly used for the purpose of reaching the target value. The present guideline also provides blood lipid management strategies for special populations. We aim to provide guidance for primary healthcare professionals to carry out blood lipid management, and comprehensively improve their ability on blood lipid management, and thereby improve the primary and secondary prevention of ASCVD in China.
Interpretation of Global Strategy for the Diagnosis，Treatment，Management and Prevention of Chronic Obstructive Pulmonary Disease 2022 Report
Global initiative for chronic obstructive lung disease (GOLD) 2022 report was released on November 15, 2021. In general, chronic obstructive pulmonary disease (COPD) diagnosis, assessment and individualized therapy are the same as GOLD 2021, with corresponding content added in ten aspects. The article introduces and interprets the new content.
在2型糖尿病（T2DM）患者的综合管理中，运动是生活方式干预的主要形式之一。我国目前仍然缺乏符合中国国情且纳入最新研究证据的T2DM运动治疗指南。为此，国家老年医学中心、中华医学会糖尿病学分会和中国体育科学学会联合组织国内内分泌及代谢病学、运动医学、康复医学、医学营养、老年医学等相关领域专家团队，系统整理了近年来国内外高质量文献，编写了《中国2型糖尿病运动治疗指南（2024版）》，旨在为临床医师、糖尿病教育护士等糖尿病防控人员提供安全、有效的T2DM运动指导。该指南包括T2DM运动治疗的基本原则、急慢性并发症、共患疾病、常用药物、运动时机、运动中血糖监测、运动营养、运动损伤、运动依从性及数字医疗等，共76条推荐意见。该指南具有较强实用性和可操作性，期望能为中国T2DM患者提供科学、规范的运动治疗方案。
China has attached importance to the prevention and treatment of chronic obstructive pulmonary disease (COPD) , a major chronic respiratory disease. An in-depth discussion of the immunopathogenesis of COPD and intervening the identified key targets may be new ideas for the prevention and treatment of COPD. Based on the relevant evidence of commonly used immunomodulatory agents for COPD, and the status and trend of development of immunomodulators for COPD, the Writing Group for the Expert Consensus of Immunemodulatory Therapies for Chronic Obstructive Pulmonary Disease proposed the following four recommendations for treating COPD with immunomodulatory therapies: (1) bacterial lysates, phosphodiesterase inhibitors, macrolides and other biological and chemical agents have immunomodulatory efects on COPD by enhancing immune function and immune cell activity; (2) vaccination against influenza and pneumococcal infection could reduce the probability of acute exacerbation of COPD and mortality; (3) statins and vitamin D may be partially effective in COPD owing to their immunomodulatory actions, but need to be verified further due to quite insufficient relevant evidence and reported adverse reactions; (4) Chinese medicine compound and Cordyceps preparations may improve the quality of life and reduce the probability of acute exacerbationsin patients with stable COPD by regulating immune function and improving immune cell activity.The main purpose of this consensus is to greatly promote the clinical treatment of COPD using immunomodulatory therapies in China.
Hypertension, type 2 diabetes mellitus (T2DM), and dyslipidemia are collectively referred to as the "three highs", which often coexist in the same individual. It significantly increases the risk of hospitalization, death, and relevant burdens for affected people. It is necessary to jointly control the risk and standardize the treatment of hypertension, T2DM and dyslipidemia. Primary healthcare institutions have become the main battlefield for the prevention and treatment of chronic diseases. Existing clinical evidence provides important insights into the prevention, treatment, and management of the "three highs", although norms, consensus, and guidelines for the co-management of the "three highs" in primary healthcare institutions at domestic and foreign are current not available. Four academic organizations led by Beijing Hypertension Association organized primary healthcare workers and invited experts and scholars from medical fields of cardiovascular diseases, endocrine, pharmacy, and public health services to participate in the consensus. Through widely soliciting clinical practice needs of primary healthcare workers, integrating and evaluating the evidence related to the prevention and treatment of the "three highs" in primary healthcare institutions, the consensus for primary healthcare in the prevention and treatment of the "three highs" including 21 opinions was developed after multiple rounds of discussions, revisions, and voting. The recommended opinions of this consensus aim to improve the awareness and ability of primary healthcare workers in the prevention and treatment of the "three highs", provide scientific strategic support, implement management with primary healthcare characteristics, and lay a solid foundation for comorbidity co-management.
Diabetes is a serious public health problem worldwide. The prevalence of chronic kidney disease (CKD) secondary to type 2 diabetes mellitus (T2DM) is growing with the increase of T2DM prevalence. There is no comprehensive guideline on medication safety in polypharmacy in patients with T2DM-related CKD. This consensus provides guidance on safety issues in polypharmacy for clinical pharmacists and Chinese patients with T2DM-related CKD, and a summary of the information on usage and dosage, and related pharmaceutical characteristics of drugs as well as medication for special populations for supporting clinical medical workers in delivering standardized medication services.
Diabetic microvascular disease (DMiVD) is the most common chronic complication of diabetes mellitus, and early identification and effective intervention can significantly improve patients' quality of life and prognosis. The Diabetes and Microcirculation Professional Committee of Chinese Society of Microcirculation and the Primary Endocrine and Metabolic Diseases Group of the Chinese Society of Endocrinology have convened experts in the field to revise the Expert Consensus on Screening and Prevention of Diabetic Microvascular Diseases for Primary Care (2024), based on the 2021 edition, considering the latest research advances and the specific needs of primary care. This consensus elaborates the screening methods, comprehensive management and prevention strategies for DMiVD (diabetic retinopathy, diabetic kidney disease, distal symmetric polyneuropathy and diabetic cardiomyopathy), clarifies the graded diagnosis and treatment and referral processes, emphasizes the importance of preventing and treating DMiVD, and offers guidance and recommendations for physicians, particularly primary care physicians and general practitioners. The aim is to reduce the incidence, progression, and disability associated with DMiVD, ultimately lowering morbidity and mortality rates.
Global initiative for chronic obstructive lung disease (GOLD) 2024 report was released on November 13th, 2023. In general, the definition, diagnosis, assessment, and therapy of chronic obstructive pulmonary disease (COPD) are the same as GOLD 2023, with corresponding content added in ten aspects, including the expansion of the information about PRISm, a new section on hyperinflation, further clarification about pre-bronchodilator spirometry, a new section on screening for COPD in targeted populations, the update of blood eosinophil count, the update of interstitial lung abnormalities, the revision of the section on smoking cessation, the update of vaccination recommendations for people with COPD, the expansion of managing inhaled therapy, and the addition of pharmacotherapies for smoking cessation. The article introduces and interprets the new contents.
Ulinastatin is mainly applied in the treatment of acute pancreatitis, but also in other common clinical critical illnesses such as shock, sepsis, evere pneumonia, cute respiratory distress syndrome, several acute poisoning, severe heat stroke, severe burns, severe trauma, and patients with sudden cardiac arrest for its roles in proteolytic enzymes inhibition and inflammatory responses regulation, which has been recommended by several guidelines/expert consensus on the diagnose and treatment of common clinical critical illness. However, there is currently a lack of consensus on the rational use of ulinastatin in terms of indications, usage, dosage, and others. Therefore, in order to promote the standardized application of ulinastatin, the expert group of expert consensus on the application of ulinastatin in common clinical critical illness summarized the mechanism, pharmacokinetics, indications of ulinastatin and its application methods in the treatment of common clinical critical illness, in order to provide a reference for the rational application of ulinastatin in clinical practice.
Schizophrenia is a chronic, recurrent and disabling psychotic disorder. Enhancing patient adherence and preventing recurrence are the key factors of treating schizophrenia, and the core determinants of prognosis and social functional recovery of these patients. Recommended by guidelines/consensuses as one treatment for schizophrenia, long-acting injectable (LAI) antipsychotics have been an important intervention for treating schizophrenia and for preventing its recurrence. At the same time, as community settings are important sites for the rehabilitation of schizophrenia, considerable efforts have been made to explore models of community-based management of schizophrenia. Currently, the use of LAI antipsychotics in community-based management of schizophrenia has been highlighted in multiple policies and documents of China, but its application is negatively influenced partially by community physicians' insufficient understanding and application skills regarding LAI antipsychotics, which has become a bottleneck that hinders the comprehensive rehabilitation of schizophrenics. In view of this, a consensus was developed based on clinical evidence, previous guidelines and consensuses, expert individual practice and features of community settings in China, by a group of 13 experts, including psychiatrists from the Chinese Schizophrenia Coordination Group, Chinese Society of Psychiatry, and general medicine experts from the Chinese Society of General Practice. This consensus will significantly contribute to the solving of problems in the use of LAI antipsychotics for community-based management of schizophrenia, and the improvement of patient adherence and prognosis.
Asthma is a serious health problem affecting people of all ages worldwide. To address asthma, the Global Initiative for Asthma Expert Group published the Global Strategy for Asthma Management and Prevention in 1995, and an updated version (GINA 2022) with new evidence being incorporated, on the World Asthma Day, May 3, 2022. Asthma prevalence is increasing but is unsatisfactorily controlled generally in China. We mainly interpreted the update points in the GINA 2022, discussed the management of asthma during the COVID-19 pandemic, and assessed the significance of the GINA 2022 for the diagnosis and treatment of asthma in China.
As China enters a deep aging society, falls and fall-related injuries in older adults have gained increased attention, with increasing emergence of relevant studies, and continuous updates in relevant guidelines. In 2022, The World Falls Task Force assembled 96 experts from 39 countries to develop the World Guidelines for Falls Prevention and Management for Older Adults: a Global Initiative. The guidelines were developed using the person-centered methodology and the latest evidence on e-health for the prevention of falls, with full consideration of the needs of fall management of older adults, and their caregivers and other stakeholders' perspectives on preventing falls in older adults, as well as the guideline applicability in various care settings and locations with limited resources, which provide new clinical recommendations on the screening, assessment, and management of risk for falls among community-dwelling older adults. This paper offers an in-depth interpretation of the guidelines and an analysis of the effective practical guidance in the guidelines, providing practical guidance for Chinese physicians, nurses and community health workers to prevent and manage falls in older adults.
When insomnia and obstructive sleep apnea (OSA) coexist, it is referred to as comorbid insomnia and obstructive sleep apnea (COMISA). The prevalence of COMISA in the general population ranges from 0.6% to 19.3%. It is primarily characterized by difficulty falling asleep, frequent nighttime awakenings, early morning awakening, poor sleep quality, snoring or apnea during sleep, unrefreshing or nonrestorative sleep, excessive daytime sleepiness, fatigue, attention impairment, memory impairment, emotional disorders, and impaired quality of life. COMISA can lead to adverse outcomes in multiple systems and increase all-cause mortality. Therefore, it is significant to establish a guidline for the diagnosis, differential diagnosis, and standardized treatment of COMISA. The guideline was organized by the Chinese Academy Society of Sleep Medicine, Chinese Medical Doctor Association and Sleep Medicine Group, China Neurologist Association. It was formed by reviewing domestic and international COMISA diagnosis and treatment practices, through literature evidence review, and after extensive discussion. The guideline summarized the epidemiology, etiology and risk factors, pathophysiological mechanisms, clinical manifestations, assessment methods, diagnosis, differential diagnosis, and treatment studies of COMISA, providing a basis for decision-making in the diagnosis and treatment of COMISA for clinician.
In order to standardize scientific drug use in vertigo, the Vertigo Committee of the Chinese Medical Education Association established an expert group to form Expert Consensus on Betahistine Mesylate in the Treatment of Vertigo after repeated discussion based on the existing medical evidence, and combined with the rich clinical experience of experts. The consensus includes the pharmacological basis of histamines, the strength of recommendation, dosage, course, review methods, medication for special populations, adverse drug reactions and other aspects of betahistine mesylate in common vertigo diseases (such as benign paroxysmal position vertigo, Menieres disease, and vestibular neuritis, etc.) to guide doctors in clinical work.
The American Heart Association (AHA) , American College of Cardiology (ACC) and Heart Failure Society of America (HFSA) jointly released the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (hereinafter referred to as the 2022 Guideline) . In the light of the latest evidence, the essentials updated in the 2022 Guideline encompass the prevention, stages, classification, drug treatment and device-based treatment of heart failure. The 2022 Guideline is content-enriched, evidence-based, practical, and easily operable, which may greatly contribute to clinical practice in China. In response to the most concerns of clinicians, we overviewed and discussed the updates in stages, classification and drug treatment of heart failure in the new guideline.
Persistent genital arousal disorder (PGAD) and genito-pelvic dysesthesia (GPD) are jointly known as PGAD/GPD, which is a newly discovered condition in recent years, featured by spontaneous or secondary persistent genital arousal and/or dysesthesia in the genital and pelvic areas. PGAD/GPD mainly affects women, which can seriously influence the physical and mental health of the sufferers due to the specificity of its symptoms. Most patients have anxiety, depression, and even the suicidal tendency. The medical community abroad has paid attention to PGAD/GPD, and included it in the International Classification of Diseases-11th Revision (ICD-11) . Given the fact that this newly discovered condition is under-recognized among domestic health providers at present, we summarized the current research on PGAD/GPD abroad and introduced the epidemiological characteristics, pathophysiological mechanisms, diagnosis and treatment methods of PGAD/GPD based on the review of the latest expert consensus of the International Society for the Study of Women's Sexual Health (ISSWSH) , and discussed the future research direction of PGAD/GPD and the coping strategies that should be taken by the domestic medical community, with a view to arousing medical workers' attention to the disease in China.
Sleep disorders, especially insomnia and sleep behavior disorders, are highly prevalent in children with autism spectrum disorder (ASD) , which cause a wide range of detrimental effects on the children and their families. Several international professional organizations have highlighted integrating sleep disorders into the comprehensive evaluation and treatment in children with ASD, and developed relevant clinical guidelines or expert consensuses, such as the A Practice Pathway for the Identification, Evaluation, and Management of Insomnia in Children and Adolescents with Autism Spectrum Disorders by the Autism Treatment Network (ATN) , Autism: the Management and Support of Children and Young People on the Autism Spectrum by the National Institute for Health and care Excellence (NICE) , and Practice Guideline: Treatment for Insomnia and Disrupted Sleep Behavior in Children and Adolescents with Autism Spectrum Disorder by the American Academy of Neurology (AAN) . However, there is no applicable clinical guideline or expert consensus for sleep disorders among Chinese children with ASD, which greatly restricts the development of relevant clinical practice. We interpreted the above-mentioned two guidelines and one consensus, focusing mainly on several aspects, such as the levels of evidence and strength of recommendations, the definition of sleep disorders and associated factors, and behavioral treatments and melatonin-based therapies. It is hoped that our endeavors will contribute to the diagnosis and management of sleep disorders in Chinese children with ASD and the development of relevant clinical guidelines or expert consensuses.
In China, idiopathic membranous nephropathy (IMN) accounts for 24.9% of glomerular diseases, the second highest share, and is increasing year by year. Chinese medicine has been widely used in the clinical practice of IMN. However, there are no evidence-based practice guidelines for the treatment of IMN with Chinese medicine. This guideline followed the methods and steps of the guideline development manual. The level of the body of the evidence was assessed by the GRADE. An outline of the clinical questions was formulated through interviews with leading Chinese medicine experts and a review of relevant clinical guidelines. Based on the results of a systematic review of authoritative textbooks and clinical research literature, a clinical question list, a clinical outcome assessment index for IMN, and a list of types of Chinese medicine syndromes were developed, and a national expert survey was conducted to identify the clinical questions included in this guideline. A consensus meeting was held to finalize 10 recommendations for treating IMN with Chinese medicine. This guideline focuses on the clinical practice of Chinese medicine in the treatment of IMN, and is applicable to all levels of Chinese medicine and integrated Chinese and Western medicine institutions, as well as medical institutions and healthcare workers who provide Chinese medicine services.
Chronic obstructive pulmonary disease (COPD) is a common, chronic heterogeneous airway disease. Although recent years have witnessed growing advances in both COPD research and management, there are still many difficulties need to be solved urgently. In view of this, the Lancet published Towards the Elimination of Chronic Obstructive Pulmonary Disease in September 2022, a document in which new ideas on the recognition, diagnosis, assessment and individualized treatment of COPD and relevant clinical guidance were proposed. This article focuses on the introduction and interpretation of the classification, diagnostic criteria and diagnostic recommendations of COPD in this document, the acute exacerbation of COPD and the move towards elimination of COPD, hoping to provide insights into COPD research and management conducted by Chinese clinical workers.
Current Status and Challenges of Cervical Cancer Treatment：from Clinical Guidelines to Real-world Study
Cervical cancer is a type of malignancy that severely threatens women's health. For invasive cervical cancer, standardized preoperative staging and assessment are essential before the start of treatment. With regard toearly cervical cancer, surgery is the major treatment, with considerations for the latest updates in relevant guidelines, and the determination of extent of resection as well as the selection of proper surgical approach. For advanced or relapsed cervical cancer, radiotherapy and chemotherapy are the main treatments. However, there are many challenges and controversies regarding the treatment and clinical research of cervical cancer. We mainly discussed the present status and challenges of cervical cancer diagnosis and treatment based on clinical guidelines and practices, aiming at bettering the real-world practice with the support of clinical guidelines.
Chinese Consensus on Diagnosis and Assessment of Sleep Apnea Syndrome in Older Adults
It is a necessary trend to improve the quality of life of rapidly increasing number of older adults. Sleep disorders are significantly associated with the quality of life in older adults, among which sleep apnea syndrome (SAS) is second only to insomnia, which is an inducer of multiple diseases, and directly associated with many chronic diseases, such as cardiovascular and cerebrovascular diseases, Alzheimer's disease, metabolic abnormalities, respiratory diseases, even leads to sudden death. So SAS in older adults should be given great attention by the whole society. With this in mind, the Chinese Association of Geriatric Sleep Medicine, Chinese Geriatrics Society invited Chinese sleep medicine experts to develop a consensus on the classification, risk factors, clinical symptoms, diagnosis and assessment methods, diagnostic procedures as well as complications of SAS in older adults based on a review of relevant clinical studies, aiming to provide a reference for the standardization of SAS diagnosis and assessment in China.
Chronic obstructive pulmonary disease (COPD) is one of the major chronic disease seriously affecting the health of Chinese residents. There are national and international guidelines and consensus on the diagnosis, treatment and management of COPD. However, there is no expert consensus on integrated traditional Chinese and western medicine management for COPD by now. Therefore, Chinese and western medicine experts with rich experience in the diagnosis and treatment of COPD in China were invited to formulate this consensus based on relevant domestic and foreign guidelines, consensus and personal experience, which includes early recognition and diagnosis of COPD, disease assessment, integrated traditional Chinese and western medicine treatment for stable COPD, evaluation, intervention measures of traditional Chinese and modern medicine, follow-up and management of acute exacerbation of COPD, so as to further improve the level of diagnosis, treatment and management of COPD in China.
The prevention and delay of disability is important for promoting healthy aging. Exercise intervention is an efficient strategy for disability prevention. Besides, exercise intervention presents significant therapeutic advantages and broad application prospects due to low cost, low implementation difficulty, high acceptance and wide application scenarios. Therefore, Nursing Group of Chinese Society of Geriatrics, Committee on Geriatric Nursing of Chinese Association of Geriatric Research, China Gerontological Nursing Alliance, National Center of Gerontology, Institute of Geriatric Medicine of Chinese Academy of Medical Sciences jointly developed and published Clinical Practice Guidelines for Exercise Interventions for the Prevention of Disability in Older Adults (2023). According to the methodologies specified in WHO Handbook for Guideline Development, the guidelines finally involve 32 recommendations and 18 clinical issues containing exercise principles, effectiveness and plans of different types of exercise, facilitators and barriers during exercise, aiming to provide a reference for the development and implementation of exercise programs for older adults at risk of disability and standardize clinical practice, thus promoting the gateway to improving physical function of the older adults, reducing the prevalence of disability, improving quality of life, contributing to healthy aging.
Evidence-based clinical guidelines are important resources for promoting the provision of high-quality and effective general practice services. Research on the development, application and effectiveness evaluation of guidelines in general practice is insufficient.
To understand the development and application of international guidelines in general practice, informing the development and utilization of relevant guidelines in China.
The PubMed database was systematically searched from August to September 2022 for studies in English related to the development, application and effectiveness of guidelines in general practice published during January 1, 2012 to September 7, 2022. The author information and focused issues as well as publication journals of the studies were extracted. And associated factors of the development, distribution and use, and effectiveness of guidelines were reviewed.
(1) A number of countries, including China, conducted the research using quantitative, qualitative, literature review and theoretical methods. (2) Organisations of general practitioners (GPs) and researchers in general practice leading or participating in guideline development, can improve the guideline acceptability and applicability, and the integration of physician experiences and patient preferences in shaping the guideline. General practice consensus is an appropriate type of the guideline. Referral recommendation is one key component of the guidelines. Guideline analysis and adaptation can be used as a strategy for GPs training. (3) Compared with specialty guidelines, the application of guidelines in general practice has been affected by more factors. Problem-oriented and self-guided guideline trainings are beneficial to the improvement of guideline compliance. Clinical audits and evidence-based medicine journal clubs are common and effective approaches for promoting guideline implementation. GPs' feedback on the guideline contributes to continuous improvement of the guidelines. (4) The impact of these guidelines on GPs' practice behaviour can be assessed observationally, while that on patient outcomes requires to be assessed using more rigorous and complex study designs.
GPs' participation in the development, implementation and evaluation of the guidelines is an enviable trend of the development in evidence-based general practice. GPs' experience and humanism, patients' preferences and expectations, and various internal and external factors associated with general practice, all need to be incorporated into the development, implementation, and evaluation of the guidelines, under collaboration with methodological experts.
Cognitive dysfunction refers to the functional impairment in one or more cognitive domains, mostly occurs in older adults. Cognitive dysfunction can commonly be divided into subjective cognitive decline (SCD), mild cognitive impairment (MCI) and dementia, depending on the degree of cognitive impairment. People with SCD or MCI have a higher risk of dementia, which seriously affects their quality of life, and imposes a huge burden on families and society. Numerous studies have demonstrated that physical activity is one effective non-pharmacological intervention for cognitive dysfunction, but there are no uniform standards for physical activity programs for cognitive dysfunction worldwide, and China still has no physical activity guidelines based on the values and preferences of older adults with cognitive dysfunction, partially impeding the dissemination and application of relevant evidence. In view of this, we developed a guideline containing eight recommendations that is applicable in China, namely the Clinical Practice Guideline on Non-pharmacological Interventions for Older Adults with Cognitive Dysfunction: Physical Activity, by the use of existing evidence, and the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework combined with values and preferences of Chinese older adults with cognitive dysfunction. This guideline will contribute to the reduction of the incidence of cognitive dysfunction, and preventing or slowing the progression of cognitive dysfunction to dementia.
People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure, atherosclerotic cardiovascular disease, heart failure, and premature mortality. The American Diabetes Association (ADA) and the Kidney Disease: Improving Global Outcomes (KDIGO) established joint group, and integration of evidence-based recommendations for diabetes management in patients with CKD in accordance with the ADA 2022 standards of medical care in diabetes and KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD, and to form the Diabetes Management in Chronic Kidney Disease: a Consensus Report by the ADA and KDIGO. The consensus not only re-emphasizes the published guidelines for screening and diagnosis of CKD, glycemia monitoring, lifestyle therapies, treatment goals, and pharmacologic management, but also specifically emphasizes the importance of comprehensive care in which pharmacotherapy based on a foundation of healthy lifestyle. The consensus states seven core recommendations which provide specific guidance for the use of renin-angiotensin system inhibitors, metformin, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineral corticoid receptor antagonist. These areas of consensus provide clear direction for implementation of care to improve clinical outcomes of people with diabetes and CKD. Focusing on the main contents of the consensus, we interpreted main recommendations in order to provide concise and practical guidance for clinicians, to achieve the goal of improving the prognosis of patients with diabetes mellitus complicated with CKD.
The guidelines on physical activities in individuals with type 2 diabetes, a common chronic metabolic disease, have been updated continuously, and relevant recommendations from them are increasingly improved, but there are still difficulties in these people's daily activities need to be addressed. In February 2022, the American College of Sports Medicine and the American Diabetes Association issued the Exercise/Physical Activity in Individuals with Type 2 Diabetes (EPAIT2D) by updating the Exercise and Type 2 Diabetes, a statement jointly published by them in 2010, which provides a concise summary of new clinical recommendations on age-specific physical activity, optimal timing of activities, effectiveness of medical intervention and physical activity, and precautions regarding physical activities and diets in type 2 diabetics. We interpreted the essentials and key updated contents of the EPAIT2D, and put forward recommendations on clinical delivery of exercise/physical activity interventions targeting Chinese type 2 diabetics.
The clinical and translational research of pulmonary hypertension (PH) has been continuously deepened, which has promoted the updating of PH related guidelines. On August 26, 2022, the European Society of Cardiology (ESC) and the Respiratory Society (ERS) jointly released the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension (hereinafter referred to as the "2022 ESC/ERS Guidelines") . In January 2021, Chinese Thoracic Society and Chinese Association of Chest Physicians jointly released the Chinese Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension (2021 Edition) (hereinafter referred to as the "Chinese Guidelines") , in which a lot of recommendations were put forward in line with China's national conditions combining with the research at home and abroad at that time. This paper will focus on the interpretation of the update points of the ESC/ERS Guidelines in combination with the relevant contents of the Chinese Guidelines.
Special Issue:guidebook/guide Interpretation
